ID   PK3CA_HUMAN             Reviewed;        1068 AA.
AC   P42336; Q14CW1; Q99762;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;
DE            Short=PI3-kinase subunit alpha;
DE            Short=PI3K-alpha;
DE            Short=PI3Kalpha;
DE            Short=PtdIns-3-kinase subunit alpha;
DE            EC=2.7.1.153 {ECO:0000250|UniProtKB:P32871};
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;
DE            Short=PtdIns-3-kinase subunit p110-alpha;
DE            Short=p110alpha;
DE   AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide;
DE   AltName: Full=Serine/threonine protein kinase PIK3CA;
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:P32871};
GN   Name=PIK3CA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332.
RX   PubMed=7713498; DOI=10.1006/geno.1994.1655;
RA   Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R.,
RA   Rocchi M., Waterfield M.;
RT   "Molecular cloning, cDNA sequence, and chromosomal localization of the
RT   human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene.";
RL   Genomics 24:472-477(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9043658; DOI=10.1016/S0968-0896(96)00196-4;
RA   Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M.,
RA   Oliff A., Heimbrook D.C.;
RT   "Cloning and mutagenesis of the p110 alpha subunit of human
RT   phosphoinositide 3'-hydroxykinase.";
RL   Bioorg. Med. Chem. 5:65-74(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH APPL1.
RX   PubMed=10490823; DOI=10.1038/sj.onc.1203080;
RA   Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A.,
RA   Testa J.R.;
RT   "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an
RT   adaptor molecule that interacts with the oncoprotein-serine/threonine
RT   kinase AKT2.";
RL   Oncogene 18:4891-4898(1999).
RN   [5]
RP   FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS
RP   LYS-545 AND ARG-1047.
RX   PubMed=21708979; DOI=10.1083/jcb.201009126;
RA   Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M.,
RA   Kouchi Z., Nakamura Y., Sakai R., Fukami K.;
RT   "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha}
RT   regulates invadopodia formation.";
RL   J. Cell Biol. 193:1275-1288(2011).
RN   [6]
RP   INTERACTION WITH FAM83B.
RX   PubMed=23676467;
RA   Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A.,
RA   Jackson M.W.;
RT   "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates
RT   to promote epithelial cell transformation and resistance to targeted
RT   therapies.";
RL   Oncotarget 4:729-738(2013).
RN   [7]
RP   REVIEW ON CANCER.
RX   PubMed=18418043; DOI=10.4161/cc.7.9.5817;
RA   Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.;
RT   "Insights into the oncogenic effects of PIK3CA mutations from the
RT   structure of p110alpha/p85alpha.";
RL   Cell Cycle 7:1151-1156(2008).
RN   [8]
RP   REVIEW ON FUNCTION, AND REVIEW ON CANCER.
RX   PubMed=18794883; DOI=10.1038/onc.2008.244;
RA   Zhao L., Vogt P.K.;
RT   "Class I PI3K in oncogenic cellular transformation.";
RL   Oncogene 27:5486-5496(2008).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007;
RA   Jia S., Roberts T.M., Zhao J.J.;
RT   "Should individual PI3 kinase isoforms be targeted in cancer?";
RL   Curr. Opin. Cell Biol. 21:199-208(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND
RP   DOMAINS.
RX   PubMed=18079394; DOI=10.1126/science.1150799;
RA   Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y.,
RA   Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B.,
RA   Amzel L.M.;
RT   "The structure of a human p110alpha/p85alpha complex elucidates the
RT   effects of oncogenic PI3Kalpha mutations.";
RL   Science 318:1744-1748(2007).
RN   [11]
RP   STRUCTURE BY NMR OF 331-481.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C2 domain from human PI3-kinase p110
RT   subunit alpha.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX
RP   WITH WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION
RP   OF VARIANT ARG-1047, AND DOMAINS.
RX   PubMed=19805105; DOI=10.1073/pnas.0908444106;
RA   Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I.,
RA   Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.;
RT   "A frequent kinase domain mutation that changes the interaction
RT   between PI3Kalpha and the membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009).
RN   [13]
RP   VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047;
RP   LEU-1047 AND TYR-1065.
RX   PubMed=15289301; DOI=10.1158/0008-5472.CAN-04-1170;
RA   Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M.,
RA   McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.;
RT   "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade
RT   astrocytomas, and medulloblastomas.";
RL   Cancer Res. 64:5048-5050(2004).
RN   [14]
RP   INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546;
RP   GLU-546; ARG-1047 AND LEU-1047.
RX   PubMed=15520168; DOI=10.1158/0008-5472.CAN-04-2933;
RA   Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G.,
RA   Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B.,
RA   Phillips W.A.;
RT   "Mutation of the PIK3CA gene in ovarian and breast cancer.";
RL   Cancer Res. 64:7678-7681(2004).
RN   [15]
RP   VARIANT CANCER ARG-1047.
RX   PubMed=15016963; DOI=10.1126/science.1096502;
RA   Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S.,
RA   Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V.,
RA   Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E.;
RT   "High frequency of mutations of the PIK3CA gene in human cancers.";
RL   Science 304:554-554(2004).
RN   [16]
RP   VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025.
RX   PubMed=15924253; DOI=10.1007/s00401-005-1000-1;
RA   Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.;
RT   "PIK3CA mutations in glioblastoma multiforme.";
RL   Acta Neuropathol. 109:639-642(2005).
RN   [17]
RP   VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047.
RX   PubMed=15784156; DOI=10.1186/1471-2407-5-29;
RA   Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M.,
RA   So S., Chen X., Yuen S.T., Leung S.Y.;
RT   "Mutations of PIK3CA in gastric adenocarcinoma.";
RL   BMC Cancer 5:29-29(2005).
RN   [18]
RP   INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38;
RP   VAL-106; ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047.
RX   PubMed=15930273; DOI=10.1158/0008-5472.CAN-04-4114;
RA   Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J.,
RA   Ohta M., Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M.,
RA   Kawabe T., Omata M.;
RT   "Functional analysis of PIK3CA gene mutations in human colorectal
RT   cancer.";
RL   Cancer Res. 65:4562-4567(2005).
RN   [19]
RP   VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007;
RP   HIS-1021; CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050;
RP   LYS-1052 AND LEU-1065.
RX   PubMed=16322209; DOI=10.1158/0008-5472.CAN-05-2620;
RA   Oda K., Stokoe D., Taketani Y., McCormick F.;
RT   "High frequency of coexistent mutations of PIK3CA and PTEN genes in
RT   endometrial carcinoma.";
RL   Cancer Res. 65:10669-10673(2005).
RN   [20]
RP   INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545;
RP   GLN-1023; ARG-1047 AND LEU-1047.
RX   PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022;
RA   Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G.,
RA   Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R.,
RA   Seruca R.;
RT   "The prevalence of PIK3CA mutations in gastric and colon cancer.";
RL   Eur. J. Cancer 41:1649-1654(2005).
RN   [21]
RP   VARIANTS CANCER LYS-545 AND ARG-1047.
RX   PubMed=15712344; DOI=10.1002/humu.9316;
RA   Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.;
RT   "PIK3CA mutations in advanced ovarian carcinomas.";
RL   Hum. Mutat. 25:322-322(2005).
RN   [22]
RP   VARIANT HCC ALA-545.
RX   PubMed=15608678; DOI=10.1038/sj.onc.1208304;
RA   Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W.,
RA   Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.;
RT   "PIK3CA gene is frequently mutated in breast carcinomas and
RT   hepatocellular carcinomas.";
RL   Oncogene 24:1477-1480(2005).
RN   [23]
RP   VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT
RP   MET-391.
RX   PubMed=16533766; DOI=10.1158/1078-0432.CCR-05-2173;
RA   Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S.,
RA   Bennett B.P., Su G.H.;
RT   "PIK3CA mutations in head and neck squamous cell carcinoma.";
RL   Clin. Cancer Res. 12:1441-1446(2006).
RN   [24]
RP   VARIANT CANCER ARG-1047.
RX   PubMed=16114017; DOI=10.1002/ijc.21444;
RA   Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.;
RT   "PIK3CA mutations in nasopharyngeal carcinoma.";
RL   Int. J. Cancer 118:1065-1067(2006).
RN   [25]
RP   VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047.
RX   PubMed=16353168; DOI=10.1002/path.1908;
RA   Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D.,
RA   Fresu G., Salvatore S., Cuccurullo F., Mezzetti A., Campani D.,
RA   Marchetti A.;
RT   "PIK3CA mutation and histological type in breast carcinoma: high
RT   frequency of mutations in lobular carcinoma.";
RL   J. Pathol. 208:350-355(2006).
RN   [26]
RP   CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047.
RX   PubMed=16432179; DOI=10.1073/pnas.0510857103;
RA   Bader A.G., Kang S., Vogt P.K.;
RT   "Cancer-specific mutations in PIK3CA are oncogenic in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006).
RN   [27]
RP   VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047.
RX   PubMed=17673550; DOI=10.1073/pnas.0705218104;
RA   Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E.,
RA   Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R.,
RA   Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A.,
RA   Real F.X.;
RT   "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic
RT   keratoses with a characteristic mutation pattern.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007).
RN   [28]
RP   VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047.
RX   PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006;
RA   Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J.,
RA   Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L.,
RA   Kozakewich H.P., Warman M.L.;
RT   "Somatic mosaic activating mutations in PIK3CA cause CLOVES
RT   syndrome.";
RL   Am. J. Hum. Genet. 90:1108-1115(2012).
RN   [29]
RP   VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL;
RP   LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043;
RP   TYR-1047 AND SER-1049.
RX   PubMed=22729224; DOI=10.1038/ng.2331;
RA   Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D.,
RA   Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W.,
RA   Nikkel S.M., Worthylake T., Sullivan C.T., Ward T.R., Butler H.E.,
RA   Kramer N.A., Albrecht B., Armour C.M., Armstrong L., Caluseriu O.,
RA   Cytrynbaum C., Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E.,
RA   Mancini G.M., Meschino W.S., Reggin J.D., Saggar A.K.,
RA   Lerman-Sagie T., Uyanik G., Weksberg R., Zirn B., Beaulieu C.L.,
RA   Majewski J., Bulman D.E., O'Driscoll M., Shendure J., Graham J.M. Jr.,
RA   Boycott K.M., Dobyns W.B.;
RT   "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA
RT   cause a spectrum of related megalencephaly syndromes.";
RL   Nat. Genet. 44:934-940(2012).
RN   [30]
RP   VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545.
RX   PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021;
RA   Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L.,
RA   Eng C.;
RT   "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like
RT   syndromes.";
RL   Am. J. Hum. Genet. 92:76-80(2013).
RN   [31]
RP   VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112,
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=26593112; DOI=10.1002/humu.22933;
RA   Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A.,
RA   Schrock E., Dobyns W.B., O'Driscoll M.;
RT   "Identification and characterisation of a novel constitutional PIK3CA
RT   mutation in a child lacking the typical segmental overgrowth of
RT   'PIK3CA-related overgrowth spectrum' (PROS).";
RL   Hum. Mutat. 37:242-245(2016).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) that phosphorylates
CC       PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-
CC       phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-
CC       bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate
CC       (PIP3). PIP3 plays a key role by recruiting PH domain-containing
CC       proteins to the membrane, including AKT1 and PDPK1, activating
CC       signaling cascades involved in cell growth, survival,
CC       proliferation, motility and morphology. Participates in cellular
CC       signaling in response to various growth factors. Involved in the
CC       activation of AKT1 upon stimulation by receptor tyrosine kinases
CC       ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in
CC       signaling via insulin-receptor substrate (IRS) proteins. Essential
CC       in endothelial cell migration during vascular development through
CC       VEGFA signaling, possibly by regulating RhoA activity. Required
CC       for lymphatic vasculature development, possibly by binding to RAS
CC       and by activation by EGF and FGF2, but not by PDGF. Regulates
CC       invadopodia formation through the PDPK1-AKT1 pathway. Participates
CC       in cardiomyogenesis in embryonic stem cells through a AKT1
CC       pathway. Participates in vasculogenesis in embryonic stem cells
CC       through PDK1 and protein kinase C pathway. Also has serine-protein
CC       kinase activity: phosphorylates PIK3R1 (p85alpha regulatory
CC       subunit), EIF4EBP1 and HRAS. Plays a role in the positive
CC       regulation of phagocytosis and pinocytosis (By similarity).
CC       {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:21708979,
CC       ECO:0000269|PubMed:26593112}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       trisphosphate. {ECO:0000250|UniProtKB:P32871}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000250|UniProtKB:P32871}.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85
CC       regulatory subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112).
CC       Interacts with IRS1 in nuclear extracts (By similarity). Interacts
CC       with RUFY3 (By similarity). Interacts with RASD2 (By similarity).
CC       Interacts with APPL1. Interacts with HRAS and KRAS (By
CC       similarity). Interaction with HRAS/KRAS is required for PI3K
CC       pathway signaling and cell proliferation stimulated by EGF and
CC       FGF2 (By similarity). Interacts with FAM83B; activates the
CC       PI3K/AKT signaling cascade (PubMed:23676467).
CC       {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467,
CC       ECO:0000269|PubMed:26593112}.
CC   -!- INTERACTION:
CC       P21860:ERBB3; NbExp=3; IntAct=EBI-2116585, EBI-720706;
CC       P35568:IRS1; NbExp=20; IntAct=EBI-2116585, EBI-517592;
CC       P27986:PIK3R1; NbExp=14; IntAct=EBI-2116585, EBI-79464;
CC       Q92569:PIK3R3; NbExp=4; IntAct=EBI-2116585, EBI-79893;
CC   -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with
CC       the PI3K/PI4K kinase domain. The C2 PI3K-type domain may
CC       facilitate the recruitment to the plasma membrane. The inhibitory
CC       interactions with PIK3R1 are mediated by the PI3K-ABD domain and
CC       the C2 PI3K-type domain with the iSH2 (inter-SH2) region of
CC       PIK3R1, and the C2 PI3K-type domain, the PI3K helical domain, and
CC       the PI3K/PI4K kinase domain with the nSH2 (N-terminal SH2) region
CC       of PIK3R1. {ECO:0000269|PubMed:18079394,
CC       ECO:0000269|PubMed:19805105}.
CC   -!- DISEASE: Note=PIK3CA mutations are involved in various type of
CC       cancer. Most of the cancer-associated mutations are missense
CC       mutations and map to one of the three hotspots: Glu-542; Glu-545
CC       and His-1047. Mutated isoforms participate in cellular
CC       transformation and tumorigenesis induced by oncogenic receptor
CC       tyrosine kinases (RTKs) and HRAS/KRAS. Interaction with HRAS/KRAS
CC       is required for Ras-driven tumor formation. Mutations increasing
CC       the lipid kinase activity are required for oncogenic signaling.
CC       The protein kinase activity may not be required for tumorigenesis.
CC       {ECO:0000269|PubMed:15016963, ECO:0000269|PubMed:15289301,
CC       ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344,
CC       ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253,
CC       ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075,
CC       ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209,
CC       ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179,
CC       ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550,
CC       ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979,
CC       ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:22729224}.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       {ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075}.
CC       Note=The gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal
CC       carcinoma is by far the most common type. Breast cancer is
CC       etiologically and genetically heterogeneous. Important genetic
CC       factors have been indicated by familial occurrence and bilateral
CC       involvement. Mutations at more than one locus can be involved in
CC       different families or even in the same case.
CC       {ECO:0000269|PubMed:16353168}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer
CC       defines malignancies originating from ovarian tissue. Although
CC       many histologic types of ovarian tumors have been described,
CC       epithelial ovarian carcinoma is the most common form. Ovarian
CC       cancers are often asymptomatic and the recognized signs and
CC       symptoms, even of late-stage disease, are vague. Consequently,
CC       most patients are diagnosed with advanced disease.
CC       {ECO:0000269|PubMed:15520168}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk
CC       factors for HCC are chronic hepatitis B virus (HBV) infection,
CC       chronic hepatitis C virus (HCV) infection, prolonged dietary
CC       aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to
CC       other causes. {ECO:0000269|PubMed:15608678}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common
CC       benign skin tumor. Seborrheic keratoses usually begin with the
CC       appearance of one or more sharply defined, light brown, flat
CC       macules. The lesions may be sparse or numerous. As they initially
CC       grow, they develop a velvety to finely verrucous surface, followed
CC       by an uneven warty surface with multiple plugged follicles and a
CC       dull or lackluster appearance. {ECO:0000269|PubMed:17673550}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria
CC       syndrome (MCAP) [MIM:602501]: A syndrome characterized by a
CC       spectrum of anomalies including primary megalencephaly, prenatal
CC       overgrowth, brain and body asymmetry, cutaneous vascular
CC       malformations, digital anomalies consisting of syndactyly with or
CC       without postaxial polydactyly, connective tissue dysplasia
CC       involving the skin, subcutaneous tissue, and joints, and cortical
CC       brain malformations, most distinctively polymicrogyria.
CC       {ECO:0000269|PubMed:22729224, ECO:0000269|PubMed:26593112}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations,
CC       and epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring,
CC       non-hereditary disorder characterized by asymmetric somatic
CC       hypertrophy and anomalies in multiple organs. It is defined by
CC       four main clinical findings: congenital lipomatous overgrowth,
CC       vascular malformations, epidermal nevi, and skeletal/spinal
CC       abnormalities. The presence of truncal overgrowth and
CC       characteristic patterned macrodactyly at birth differentiates
CC       CLOVE from other syndromic forms of overgrowth.
CC       {ECO:0000269|PubMed:22658544}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden
CC       syndrome, a hamartomatous polyposis syndrome with age-related
CC       penetrance. Cowden syndrome is characterized by hamartomatous
CC       lesions affecting derivatives of ectodermal, mesodermal and
CC       endodermal layers, macrocephaly, facial trichilemmomas (benign
CC       tumors of the hair follicle infundibulum), acral keratoses,
CC       papillomatous papules, and elevated risk for development of
CC       several types of malignancy, particularly breast carcinoma in
CC       women and thyroid carcinoma in both men and women. Colon cancer
CC       and renal cell carcinoma have also been reported. Hamartomas can
CC       be found in virtually every organ, but most commonly in the skin,
CC       gastrointestinal tract, breast and thyroid.
CC       {ECO:0000269|PubMed:23246288}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an
CC       oncogene derived from PIK3CA. {ECO:0000305|PubMed:18418043}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00877, ECO:0000255|PROSITE-
CC       ProRule:PRU00879, ECO:0000255|PROSITE-ProRule:PRU00880}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PIK3CAID415ch3q26.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z29090; CAA82333.1; -; mRNA.
DR   EMBL; U79143; AAB39753.1; -; mRNA.
DR   EMBL; BC113601; AAI13602.1; -; mRNA.
DR   EMBL; BC113603; AAI13604.1; -; mRNA.
DR   CCDS; CCDS43171.1; -.
DR   PIR; I38110; I38110.
DR   RefSeq; NP_006209.2; NM_006218.3.
DR   RefSeq; XP_006713721.1; XM_006713658.3.
DR   RefSeq; XP_011511196.1; XM_011512894.2.
DR   UniGene; Hs.553498; -.
DR   UniGene; Hs.715194; -.
DR   UniGene; Hs.732394; -.
DR   PDB; 2ENQ; NMR; -; A=331-481.
DR   PDB; 2RD0; X-ray; 3.05 A; A=1-1068.
DR   PDB; 3HHM; X-ray; 2.80 A; A=1-1068.
DR   PDB; 3HIZ; X-ray; 3.30 A; A=1-1068.
DR   PDB; 3ZIM; X-ray; 2.85 A; A=107-1046.
DR   PDB; 4JPS; X-ray; 2.20 A; A=1-1068.
DR   PDB; 4L1B; X-ray; 2.59 A; A=1-1068.
DR   PDB; 4L23; X-ray; 2.50 A; A=1-1068.
DR   PDB; 4L2Y; X-ray; 2.80 A; A=1-1068.
DR   PDB; 4OVU; X-ray; 2.96 A; A=1-1068.
DR   PDB; 4OVV; X-ray; 3.50 A; A=1-1068.
DR   PDB; 4TUU; X-ray; 2.64 A; A=105-1048.
DR   PDB; 4TV3; X-ray; 2.85 A; A=105-1048.
DR   PDB; 4WAF; X-ray; 2.39 A; A=2-1068.
DR   PDB; 4YKN; X-ray; 2.90 A; A=2-1068.
DR   PDB; 4ZOP; X-ray; 2.62 A; A=1-1068.
DR   PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068.
DR   PDB; 5DXT; X-ray; 2.25 A; A=107-1068.
DR   PDB; 5FI4; X-ray; 2.50 A; A=1-1068.
DR   PDB; 5ITD; X-ray; 3.02 A; A=1-1068.
DR   PDB; 5SW8; X-ray; 3.30 A; A=1-1068.
DR   PDB; 5SWG; X-ray; 3.11 A; A=1-1068.
DR   PDB; 5SWO; X-ray; 3.50 A; A=1-1068.
DR   PDB; 5SWP; X-ray; 3.41 A; A=1-1068.
DR   PDB; 5SWR; X-ray; 3.31 A; A=1-1068.
DR   PDB; 5SWT; X-ray; 3.49 A; A=1-1068.
DR   PDB; 5SX8; X-ray; 3.47 A; A=1-1068.
DR   PDB; 5SX9; X-ray; 3.52 A; A=1-1068.
DR   PDB; 5SXA; X-ray; 3.35 A; A=1-1068.
DR   PDB; 5SXB; X-ray; 3.30 A; A=1-1068.
DR   PDB; 5SXC; X-ray; 3.55 A; A=1-1068.
DR   PDB; 5SXD; X-ray; 3.50 A; A=1-1068.
DR   PDB; 5SXE; X-ray; 3.51 A; A=1-1068.
DR   PDB; 5SXF; X-ray; 3.46 A; A=1-1068.
DR   PDB; 5SXI; X-ray; 3.40 A; A=1-1068.
DR   PDB; 5SXJ; X-ray; 3.42 A; A=1-1068.
DR   PDB; 5SXK; X-ray; 3.55 A; A=1-1068.
DR   PDB; 5UBR; X-ray; 2.40 A; A=107-1050.
DR   PDBsum; 2ENQ; -.
DR   PDBsum; 2RD0; -.
DR   PDBsum; 3HHM; -.
DR   PDBsum; 3HIZ; -.
DR   PDBsum; 3ZIM; -.
DR   PDBsum; 4JPS; -.
DR   PDBsum; 4L1B; -.
DR   PDBsum; 4L23; -.
DR   PDBsum; 4L2Y; -.
DR   PDBsum; 4OVU; -.
DR   PDBsum; 4OVV; -.
DR   PDBsum; 4TUU; -.
DR   PDBsum; 4TV3; -.
DR   PDBsum; 4WAF; -.
DR   PDBsum; 4YKN; -.
DR   PDBsum; 4ZOP; -.
DR   PDBsum; 5DXH; -.
DR   PDBsum; 5DXT; -.
DR   PDBsum; 5FI4; -.
DR   PDBsum; 5ITD; -.
DR   PDBsum; 5SW8; -.
DR   PDBsum; 5SWG; -.
DR   PDBsum; 5SWO; -.
DR   PDBsum; 5SWP; -.
DR   PDBsum; 5SWR; -.
DR   PDBsum; 5SWT; -.
DR   PDBsum; 5SX8; -.
DR   PDBsum; 5SX9; -.
DR   PDBsum; 5SXA; -.
DR   PDBsum; 5SXB; -.
DR   PDBsum; 5SXC; -.
DR   PDBsum; 5SXD; -.
DR   PDBsum; 5SXE; -.
DR   PDBsum; 5SXF; -.
DR   PDBsum; 5SXI; -.
DR   PDBsum; 5SXJ; -.
DR   PDBsum; 5SXK; -.
DR   PDBsum; 5UBR; -.
DR   ProteinModelPortal; P42336; -.
DR   SMR; P42336; -.
DR   BioGrid; 111308; 77.
DR   DIP; DIP-42728N; -.
DR   IntAct; P42336; 46.
DR   MINT; MINT-1367228; -.
DR   STRING; 9606.ENSP00000263967; -.
DR   BindingDB; P42336; -.
DR   ChEMBL; CHEMBL4005; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB05240; XL147.
DR   DrugBank; DB05241; XL765.
DR   GuidetoPHARMACOLOGY; 2153; -.
DR   iPTMnet; P42336; -.
DR   PhosphoSitePlus; P42336; -.
DR   BioMuta; PI3KCA; -.
DR   DMDM; 126302584; -.
DR   EPD; P42336; -.
DR   MaxQB; P42336; -.
DR   PaxDb; P42336; -.
DR   PeptideAtlas; P42336; -.
DR   PRIDE; P42336; -.
DR   DNASU; 5290; -.
DR   Ensembl; ENST00000263967; ENSP00000263967; ENSG00000121879.
DR   GeneID; 5290; -.
DR   KEGG; hsa:5290; -.
DR   UCSC; uc003fjk.4; human.
DR   CTD; 5290; -.
DR   DisGeNET; 5290; -.
DR   GeneCards; PIK3CA; -.
DR   GeneReviews; PIK3CA; -.
DR   HGNC; HGNC:8975; PIK3CA.
DR   HPA; CAB017804; -.
DR   HPA; HPA009985; -.
DR   MalaCards; PIK3CA; -.
DR   MIM; 114480; phenotype.
DR   MIM; 114500; phenotype.
DR   MIM; 114550; phenotype.
DR   MIM; 167000; phenotype.
DR   MIM; 171834; gene.
DR   MIM; 182000; phenotype.
DR   MIM; 602501; phenotype.
DR   MIM; 612918; phenotype.
DR   MIM; 615108; phenotype.
DR   neXtProt; NX_P42336; -.
DR   OpenTargets; ENSG00000121879; -.
DR   Orphanet; 140944; CLOVE syndrome.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome.
DR   Orphanet; 99802; Hemimegalencephaly.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   Orphanet; 295239; Macrodactyly of fingers, unilateral.
DR   Orphanet; 295243; Macrodactyly of toes, unilateral.
DR   Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome.
DR   Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia.
DR   PharmGKB; PA33308; -.
DR   eggNOG; KOG0904; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00760000119110; -.
DR   HOVERGEN; HBG052721; -.
DR   InParanoid; P42336; -.
DR   KO; K00922; -.
DR   OMA; PMVRAFA; -.
DR   OrthoDB; EOG091G027R; -.
DR   PhylomeDB; P42336; -.
DR   TreeFam; TF102031; -.
DR   BioCyc; MetaCyc:HS04527-MONOMER; -.
DR   BRENDA; 2.7.1.137; 2681.
DR   BRENDA; 2.7.1.153; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-373753; Nephrin interactions.
DR   Reactome; R-HSA-388841; Costimulation by the CD28 family.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; P42336; -.
DR   SIGNOR; P42336; -.
DR   ChiTaRS; PIK3CA; human.
DR   EvolutionaryTrace; P42336; -.
DR   GeneWiki; P110%CE%B1; -.
DR   GenomeRNAi; 5290; -.
DR   PRO; PR:P42336; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000121879; -.
DR   CleanEx; HS_PIK3CA; -.
DR   ExpressionAtlas; P42336; baseline and differential.
DR   Genevisible; P42336; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL.
DR   GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0035004; F:phosphatidylinositol 3-kinase activity; ISS:BHF-UCL.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0060612; P:adipose tissue development; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0044029; P:hypomethylation of CpG island; IEA:Ensembl.
DR   GO; GO:0038028; P:insulin receptor signaling pathway via phosphatidylinositol 3-kinase; TAS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; IDA:MGI.
DR   GO; GO:0030168; P:platelet activation; TAS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:2000653; P:regulation of genetic imprinting; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001944; P:vasculature development; TAS:UniProtKB.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003113; PI3K_adapt-bd_dom.
DR   InterPro; IPR002420; PI3K_C2_dom.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001263; PInositide-3_kin_accessory_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10048; PTHR10048; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51547; PI3K_C2; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Complete proteome;
KW   Disease mutation; Kinase; Nucleotide-binding; Phagocytosis;
KW   Polymorphism; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   1068       Phosphatidylinositol 4,5-bisphosphate 3-
FT                                kinase catalytic subunit alpha isoform.
FT                                /FTId=PRO_0000088785.
FT   DOMAIN       16    105       PI3K-ABD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00877}.
FT   DOMAIN      187    289       PI3K-RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00879}.
FT   DOMAIN      330    487       C2 PI3K-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00880}.
FT   DOMAIN      517    694       PIK helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00878}.
FT   DOMAIN      797   1068       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   VARIANT      38     38       R -> H (in CRC; likely involved in
FT                                disease pathogenesis; shows an increase
FT                                in lipid kinase activity; may disrupt the
FT                                interaction between the PI3K-ABD domain
FT                                and the N-terminal lobe of PI3K/PI4K
FT                                kinase domain possibly affecting the
FT                                conformation of the kinase domain;
FT                                dbSNP:rs772110575).
FT                                {ECO:0000269|PubMed:15930273}.
FT                                /FTId=VAR_026166.
FT   VARIANT      43     43       I -> V (in dbSNP:rs1051399).
FT                                {ECO:0000269|PubMed:7713498}.
FT                                /FTId=VAR_042942.
FT   VARIANT      81     81       E -> K (in MCAP).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069251.
FT   VARIANT      88     88       R -> Q (in MCAP; also found in a
FT                                glioblastoma multiforme sample;
FT                                dbSNP:rs121913287).
FT                                {ECO:0000269|PubMed:15924253,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026167.
FT   VARIANT     106    106       G -> V (in CRC; likely involved in
FT                                disease pathogenesis; shows an increase
FT                                in lipid kinase activity).
FT                                {ECO:0000269|PubMed:15930273}.
FT                                /FTId=VAR_026168.
FT   VARIANT     112    112       I -> N (in MCAP; increased
FT                                phosphatidylinositol 3-kinase signaling;
FT                                decreased interaction with p85 regulatory
FT                                subunit; no effect on protein abundance;
FT                                dbSNP:rs863225460).
FT                                {ECO:0000269|PubMed:26593112}.
FT                                /FTId=VAR_075634.
FT   VARIANT     118    118       G -> D (in CWS5; dbSNP:rs587777790).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069786.
FT   VARIANT     135    135       E -> K (in CWS5; dbSNP:rs587777791).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069787.
FT   VARIANT     218    218       E -> K (in CWS5; dbSNP:rs587777792).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069788.
FT   VARIANT     332    332       S -> R (in dbSNP:rs1051407).
FT                                {ECO:0000269|PubMed:7713498}.
FT                                /FTId=VAR_042943.
FT   VARIANT     343    343       Y -> C (found in a cancer sample; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:16533766}.
FT                                /FTId=VAR_026169.
FT   VARIANT     356    356       V -> I (in CWS5; dbSNP:rs587777793).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069789.
FT   VARIANT     364    364       G -> R (in MCAP).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069252.
FT   VARIANT     365    365       E -> K (in MCAP).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069253.
FT   VARIANT     378    378       C -> Y (in MCAP; dbSNP:rs397514565).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069254.
FT   VARIANT     382    382       R -> K (in CWS5; dbSNP:rs587777794).
FT                                {ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_069790.
FT   VARIANT     391    391       I -> M (in dbSNP:rs2230461).
FT                                {ECO:0000269|PubMed:16533766}.
FT                                /FTId=VAR_026170.
FT   VARIANT     420    420       C -> R (in CLOVE and CRC; shows an
FT                                increase in lipid kinase activity; may
FT                                increase the affinity for lipid
FT                                membranes; dbSNP:rs121913272).
FT                                {ECO:0000269|PubMed:15930273,
FT                                ECO:0000269|PubMed:22658544}.
FT                                /FTId=VAR_026171.
FT   VARIANT     453    453       E -> Q (in CRC; likely involved in
FT                                disease pathogenesis; shows an increase
FT                                in lipid kinase activity; may disrupt the
FT                                interaction of the C2 PI3K-type domain
FT                                with the iSH2 region of the p85
FT                                regulatory subunit).
FT                                {ECO:0000269|PubMed:15930273}.
FT                                /FTId=VAR_026172.
FT   VARIANT     453    453       Missing (in MCAP).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069255.
FT   VARIANT     542    542       E -> K (in CLOVE, KERSEB, CRC and BC;
FT                                also found in glioblastoma multiforme and
FT                                endometrial carcinoma; shows an increase
FT                                in lipid kinase activity; oncogenic in
FT                                vivo; occurs in the interface between the
FT                                PI3K helical domain and the nSH2 (N-
FT                                terminal SH2) region of the p85
FT                                regulatory subunit and may reduce the
FT                                inhibitory effect of p85; requires
FT                                interaction with RAS to induce cellular
FT                                transformation; dbSNP:rs121913273).
FT                                {ECO:0000269|PubMed:15289301,
FT                                ECO:0000269|PubMed:15784156,
FT                                ECO:0000269|PubMed:15924253,
FT                                ECO:0000269|PubMed:15930273,
FT                                ECO:0000269|PubMed:15994075,
FT                                ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:16353168,
FT                                ECO:0000269|PubMed:16432179,
FT                                ECO:0000269|PubMed:16533766,
FT                                ECO:0000269|PubMed:17673550,
FT                                ECO:0000269|PubMed:22658544}.
FT                                /FTId=VAR_026173.
FT   VARIANT     542    542       E -> Q (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026174.
FT   VARIANT     542    542       E -> V (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16353168}.
FT                                /FTId=VAR_026175.
FT   VARIANT     545    545       E -> A (in CWS5 and HCC; also found in a
FT                                glioblastoma multiforme sample;
FT                                dbSNP:rs121913274).
FT                                {ECO:0000269|PubMed:15608678,
FT                                ECO:0000269|PubMed:15924253,
FT                                ECO:0000269|PubMed:23246288}.
FT                                /FTId=VAR_026176.
FT   VARIANT     545    545       E -> G (in KERSEB; also found in an
FT                                endometrial carcinoma sample;
FT                                dbSNP:rs121913274).
FT                                {ECO:0000269|PubMed:15520168,
FT                                ECO:0000269|PubMed:15994075,
FT                                ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:17673550}.
FT                                /FTId=VAR_026177.
FT   VARIANT     545    545       E -> K (in MCAP, KERSEB, CRC and BC;
FT                                shows an increase in lipid kinase
FT                                activity; oncogenic in vivo; occurs in
FT                                the interface between the PI3K helical
FT                                domain and the nSH2 (N-terminal SH2)
FT                                region of the p85 regulatory subunit and
FT                                may reduce the inhibitory effect of p85;
FT                                requires interaction with RAS to induce
FT                                cellular transformation; enhances
FT                                invadopodia-mediated extracellular matrix
FT                                degradation and invasion in breast cancer
FT                                cells; dbSNP:rs104886003).
FT                                {ECO:0000269|PubMed:15289301,
FT                                ECO:0000269|PubMed:15520168,
FT                                ECO:0000269|PubMed:15712344,
FT                                ECO:0000269|PubMed:15784156,
FT                                ECO:0000269|PubMed:15930273,
FT                                ECO:0000269|PubMed:15994075,
FT                                ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:16353168,
FT                                ECO:0000269|PubMed:16432179,
FT                                ECO:0000269|PubMed:16533766,
FT                                ECO:0000269|PubMed:17673550,
FT                                ECO:0000269|PubMed:21708979,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026178.
FT   VARIANT     546    546       Q -> E (in BC; unknown pathological
FT                                significance; dbSNP:rs121913286).
FT                                {ECO:0000269|PubMed:15520168}.
FT                                /FTId=VAR_026179.
FT   VARIANT     546    546       Q -> K (in OC; unknown pathological
FT                                significance; dbSNP:rs121913286).
FT                                {ECO:0000269|PubMed:15520168}.
FT                                /FTId=VAR_026180.
FT   VARIANT     546    546       Q -> P (found in an anaplastic
FT                                astrocytoma sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15289301}.
FT                                /FTId=VAR_026181.
FT   VARIANT     546    546       Q -> R (in BC; unknown pathological
FT                                significance; dbSNP:rs397517201).
FT                                {ECO:0000269|PubMed:16353168}.
FT                                /FTId=VAR_026182.
FT   VARIANT     726    726       E -> K (in MCAP; dbSNP:rs867262025).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069256.
FT   VARIANT     914    914       G -> R (in MCAP; dbSNP:rs587776932).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069257.
FT   VARIANT    1007   1007       G -> R (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026183.
FT   VARIANT    1021   1021       Y -> C (in MCAP; also found in an
FT                                endometrial carcinoma sample;
FT                                dbSNP:rs121913288).
FT                                {ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026184.
FT   VARIANT    1021   1021       Y -> H (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026185.
FT   VARIANT    1021   1021       Y -> N (found in a glioblastoma
FT                                multiforme sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15289301}.
FT                                /FTId=VAR_026186.
FT   VARIANT    1023   1023       R -> Q (in CRC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15994075}.
FT                                /FTId=VAR_026187.
FT   VARIANT    1025   1025       T -> A (in MCAP; dbSNP:rs397517202).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069258.
FT   VARIANT    1025   1025       T -> N (found in a glioblastoma
FT                                multiforme sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15924253}.
FT                                /FTId=VAR_026188.
FT   VARIANT    1035   1035       A -> V (in MCAP; also found in an
FT                                endometrial carcinoma sample).
FT                                {ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026189.
FT   VARIANT    1043   1043       M -> I (in MCAP and CRC; also found in an
FT                                endometrial carcinoma sample; shows an
FT                                increase in lipid kinase activity;
FT                                dbSNP:rs121913283).
FT                                {ECO:0000269|PubMed:15930273,
FT                                ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026190.
FT   VARIANT    1047   1047       H -> L (in BC; unknown pathological
FT                                significance; dbSNP:rs121913279).
FT                                {ECO:0000269|PubMed:15289301,
FT                                ECO:0000269|PubMed:15520168,
FT                                ECO:0000269|PubMed:15994075,
FT                                ECO:0000269|PubMed:16353168}.
FT                                /FTId=VAR_026191.
FT   VARIANT    1047   1047       H -> R (in CLOVE, KERSEB, CRC, BC and OC;
FT                                also found in an endometrial carcinoma
FT                                sample; shows an increase in lipid kinase
FT                                activity; oncogenic in vivo; requires
FT                                binding to p85 regulatory subunit to
FT                                induce cellular transformation but not
FT                                interaction with RAS; may mimic the
FT                                conformatitonal change triggered by the
FT                                interaction with RAS; enhances
FT                                invadopodia-mediated extracellular matrix
FT                                degradation and invasion in breast cancer
FT                                cells; increases lipid kinase activity;
FT                                may alter the interaction of the PI3K/
FT                                PI4K kinase domain with the cell
FT                                membrane; dbSNP:rs121913279).
FT                                {ECO:0000269|PubMed:15016963,
FT                                ECO:0000269|PubMed:15289301,
FT                                ECO:0000269|PubMed:15520168,
FT                                ECO:0000269|PubMed:15712344,
FT                                ECO:0000269|PubMed:15784156,
FT                                ECO:0000269|PubMed:15930273,
FT                                ECO:0000269|PubMed:15994075,
FT                                ECO:0000269|PubMed:16114017,
FT                                ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:16353168,
FT                                ECO:0000269|PubMed:16432179,
FT                                ECO:0000269|PubMed:16533766,
FT                                ECO:0000269|PubMed:17673550,
FT                                ECO:0000269|PubMed:19805105,
FT                                ECO:0000269|PubMed:21708979,
FT                                ECO:0000269|PubMed:22658544}.
FT                                /FTId=VAR_026192.
FT   VARIANT    1047   1047       H -> Y (in MCAP; also found in an
FT                                endometrial carcinoma sample;
FT                                dbSNP:rs121913281).
FT                                {ECO:0000269|PubMed:16322209,
FT                                ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_026193.
FT   VARIANT    1049   1049       G -> S (in MCAP; dbSNP:rs121913277).
FT                                {ECO:0000269|PubMed:22729224}.
FT                                /FTId=VAR_069259.
FT   VARIANT    1050   1050       G -> D (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026194.
FT   VARIANT    1052   1052       T -> K (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026195.
FT   VARIANT    1065   1065       H -> L (found in an endometrial carcinoma
FT                                sample; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16322209}.
FT                                /FTId=VAR_026196.
FT   VARIANT    1065   1065       H -> Y (found in brain tumors; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:15289301}.
FT                                /FTId=VAR_026197.
FT   CONFLICT    170    170       N -> H (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       K -> R (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    286    287       ML -> KM (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    346    346       V -> L (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    723    723       K -> R (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    751    751       F -> L (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   CONFLICT    767    767       E -> K (in Ref. 1; CAA82333).
FT                                {ECO:0000305}.
FT   STRAND        5     10       {ECO:0000244|PDB:4JPS}.
FT   STRAND       13     15       {ECO:0000244|PDB:4JPS}.
FT   STRAND       18     25       {ECO:0000244|PDB:4JPS}.
FT   STRAND       27     29       {ECO:0000244|PDB:5SW8}.
FT   STRAND       31     37       {ECO:0000244|PDB:4JPS}.
FT   HELIX        42     52       {ECO:0000244|PDB:4JPS}.
FT   HELIX        53     55       {ECO:0000244|PDB:4JPS}.
FT   STRAND       56     58       {ECO:0000244|PDB:2RD0}.
FT   HELIX        59     61       {ECO:0000244|PDB:4JPS}.
FT   HELIX        65     67       {ECO:0000244|PDB:4JPS}.
FT   STRAND       69     74       {ECO:0000244|PDB:4JPS}.
FT   STRAND       75     77       {ECO:0000244|PDB:4OVU}.
FT   STRAND       79     82       {ECO:0000244|PDB:4JPS}.
FT   STRAND       86     88       {ECO:0000244|PDB:5SW8}.
FT   HELIX        89     91       {ECO:0000244|PDB:4JPS}.
FT   STRAND       94    102       {ECO:0000244|PDB:4JPS}.
FT   STRAND      105    107       {ECO:0000244|PDB:5SXA}.
FT   HELIX       108    121       {ECO:0000244|PDB:4JPS}.
FT   HELIX       126    130       {ECO:0000244|PDB:4JPS}.
FT   HELIX       134    142       {ECO:0000244|PDB:4JPS}.
FT   HELIX       144    155       {ECO:0000244|PDB:4JPS}.
FT   TURN        156    159       {ECO:0000244|PDB:4JPS}.
FT   HELIX       160    166       {ECO:0000244|PDB:4JPS}.
FT   HELIX       179    182       {ECO:0000244|PDB:4JPS}.
FT   STRAND      185    198       {ECO:0000244|PDB:4JPS}.
FT   TURN        199    202       {ECO:0000244|PDB:4JPS}.
FT   STRAND      203    212       {ECO:0000244|PDB:4JPS}.
FT   HELIX       217    226       {ECO:0000244|PDB:4JPS}.
FT   TURN        228    230       {ECO:0000244|PDB:5FI4}.
FT   STRAND      232    234       {ECO:0000244|PDB:4OVU}.
FT   HELIX       237    242       {ECO:0000244|PDB:4WAF}.
FT   TURN        243    245       {ECO:0000244|PDB:4L1B}.
FT   HELIX       246    248       {ECO:0000244|PDB:4JPS}.
FT   STRAND      249    254       {ECO:0000244|PDB:4JPS}.
FT   TURN        255    258       {ECO:0000244|PDB:3HIZ}.
FT   STRAND      263    265       {ECO:0000244|PDB:5DXH}.
FT   HELIX       267    269       {ECO:0000244|PDB:4JPS}.
FT   HELIX       271    279       {ECO:0000244|PDB:4JPS}.
FT   STRAND      284    289       {ECO:0000244|PDB:4JPS}.
FT   HELIX       290    294       {ECO:0000244|PDB:4JPS}.
FT   HELIX       306    309       {ECO:0000244|PDB:4JPS}.
FT   STRAND      319    321       {ECO:0000244|PDB:5SXA}.
FT   STRAND      323    326       {ECO:0000244|PDB:5DXT}.
FT   HELIX       327    329       {ECO:0000244|PDB:4JPS}.
FT   STRAND      332    342       {ECO:0000244|PDB:4JPS}.
FT   TURN        348    350       {ECO:0000244|PDB:4JPS}.
FT   STRAND      353    362       {ECO:0000244|PDB:4JPS}.
FT   STRAND      365    368       {ECO:0000244|PDB:4JPS}.
FT   STRAND      376    379       {ECO:0000244|PDB:4TUU}.
FT   STRAND      382    392       {ECO:0000244|PDB:4JPS}.
FT   HELIX       393    395       {ECO:0000244|PDB:4JPS}.
FT   STRAND      401    413       {ECO:0000244|PDB:4JPS}.
FT   STRAND      416    430       {ECO:0000244|PDB:4JPS}.
FT   STRAND      434    436       {ECO:0000244|PDB:4JPS}.
FT   STRAND      439    444       {ECO:0000244|PDB:4JPS}.
FT   STRAND      454    456       {ECO:0000244|PDB:3ZIM}.
FT   STRAND      458    460       {ECO:0000244|PDB:2RD0}.
FT   STRAND      468    470       {ECO:0000244|PDB:4JPS}.
FT   STRAND      472    477       {ECO:0000244|PDB:4JPS}.
FT   STRAND      481    485       {ECO:0000244|PDB:5DXT}.
FT   HELIX       489    492       {ECO:0000244|PDB:4JPS}.
FT   HELIX       495    498       {ECO:0000244|PDB:2RD0}.
FT   STRAND      504    506       {ECO:0000244|PDB:5SWP}.
FT   HELIX       508    512       {ECO:0000244|PDB:5DXT}.
FT   HELIX       513    515       {ECO:0000244|PDB:5SXB}.
FT   HELIX       517    520       {ECO:0000244|PDB:4L23}.
FT   HELIX       526    536       {ECO:0000244|PDB:4JPS}.
FT   STRAND      539    541       {ECO:0000244|PDB:4TUU}.
FT   HELIX       545    553       {ECO:0000244|PDB:4JPS}.
FT   TURN        554    557       {ECO:0000244|PDB:4JPS}.
FT   HELIX       558    560       {ECO:0000244|PDB:4JPS}.
FT   HELIX       562    564       {ECO:0000244|PDB:4JPS}.
FT   HELIX       565    571       {ECO:0000244|PDB:4JPS}.
FT   HELIX       577    589       {ECO:0000244|PDB:4JPS}.
FT   HELIX       595    598       {ECO:0000244|PDB:4JPS}.
FT   HELIX       599    602       {ECO:0000244|PDB:4JPS}.
FT   HELIX       609    622       {ECO:0000244|PDB:4JPS}.
FT   HELIX       625    638       {ECO:0000244|PDB:4JPS}.
FT   HELIX       639    641       {ECO:0000244|PDB:4JPS}.
FT   STRAND      643    646       {ECO:0000244|PDB:4JPS}.
FT   HELIX       648    657       {ECO:0000244|PDB:4JPS}.
FT   HELIX       661    672       {ECO:0000244|PDB:4JPS}.
FT   TURN        673    676       {ECO:0000244|PDB:4JPS}.
FT   TURN        678    680       {ECO:0000244|PDB:4JPS}.
FT   HELIX       681    694       {ECO:0000244|PDB:4JPS}.
FT   HELIX       698    720       {ECO:0000244|PDB:4JPS}.
FT   TURN        721    725       {ECO:0000244|PDB:4JPS}.
FT   HELIX       728    739       {ECO:0000244|PDB:4JPS}.
FT   HELIX       742    748       {ECO:0000244|PDB:4JPS}.
FT   STRAND      749    753       {ECO:0000244|PDB:4JPS}.
FT   STRAND      756    761       {ECO:0000244|PDB:4JPS}.
FT   HELIX       766    768       {ECO:0000244|PDB:4JPS}.
FT   STRAND      774    776       {ECO:0000244|PDB:3HHM}.
FT   STRAND      779    784       {ECO:0000244|PDB:4JPS}.
FT   HELIX       790    792       {ECO:0000244|PDB:4JPS}.
FT   STRAND      795    805       {ECO:0000244|PDB:4JPS}.
FT   HELIX       808    825       {ECO:0000244|PDB:4JPS}.
FT   TURN        826    828       {ECO:0000244|PDB:4JPS}.
FT   STRAND      838    842       {ECO:0000244|PDB:4JPS}.
FT   STRAND      845    849       {ECO:0000244|PDB:4JPS}.
FT   STRAND      852    856       {ECO:0000244|PDB:4JPS}.
FT   HELIX       857    861       {ECO:0000244|PDB:4JPS}.
FT   STRAND      862    864       {ECO:0000244|PDB:5SWG}.
FT   TURN        865    867       {ECO:0000244|PDB:3HHM}.
FT   HELIX       871    873       {ECO:0000244|PDB:2RD0}.
FT   HELIX       876    884       {ECO:0000244|PDB:4JPS}.
FT   HELIX       887    889       {ECO:0000244|PDB:4JPS}.
FT   HELIX       890    911       {ECO:0000244|PDB:4JPS}.
FT   STRAND      920    924       {ECO:0000244|PDB:4JPS}.
FT   STRAND      929    931       {ECO:0000244|PDB:4JPS}.
FT   TURN        938    941       {ECO:0000244|PDB:4YKN}.
FT   HELIX       942    945       {ECO:0000244|PDB:4JPS}.
FT   HELIX       958    964       {ECO:0000244|PDB:4JPS}.
FT   TURN        965    967       {ECO:0000244|PDB:4JPS}.
FT   STRAND      969    971       {ECO:0000244|PDB:4JPS}.
FT   STRAND      972    974       {ECO:0000244|PDB:5DXT}.
FT   HELIX       975    993       {ECO:0000244|PDB:4JPS}.
FT   HELIX       995   1003       {ECO:0000244|PDB:4JPS}.
FT   TURN       1004   1007       {ECO:0000244|PDB:4JPS}.
FT   STRAND     1013   1015       {ECO:0000244|PDB:4TUU}.
FT   HELIX      1016   1025       {ECO:0000244|PDB:4JPS}.
FT   TURN       1026   1029       {ECO:0000244|PDB:4JPS}.
FT   HELIX      1032   1047       {ECO:0000244|PDB:4JPS}.
FT   STRAND     1048   1050       {ECO:0000244|PDB:5SW8}.
FT   STRAND     1053   1055       {ECO:0000244|PDB:3HHM}.
FT   STRAND     1056   1058       {ECO:0000244|PDB:4JPS}.
SQ   SEQUENCE   1068 AA;  124284 MW;  041487231A9A1207 CRC64;
     MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ
     LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA
     IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH
     IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK
     LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD
     CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI
     YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC
     PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF
     SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL
     SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME
     LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN
     QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK
     QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW
     LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS
     IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS
     CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF
     LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA
     YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN
//
